Findings from the Longitudinal CINRG Becker Natural History Study.

Muscular dystrophies dystrophin muscle natural history skeletal

Journal

Journal of neuromuscular diseases
ISSN: 2214-3602
Titre abrégé: J Neuromuscul Dis
Pays: Netherlands
ID NLM: 101649948

Informations de publication

Date de publication:
17 Nov 2023
Historique:
medline: 19 11 2023
pubmed: 19 11 2023
entrez: 19 11 2023
Statut: aheadofprint

Résumé

Becker muscular dystrophy is an X-linked, genetic disorder causing progressive degeneration of skeletal and cardiac muscle, with a widely variable phenotype. A 3-year, longitudinal, prospective dataset contributed by patients with confirmed Becker muscular dystrophy was analyzed to characterize the natural history of this disorder. A better understanding of the natural history is crucial to rigorous therapeutic trials. A cohort of 83 patients with Becker muscular dystrophy (5-75 years at baseline) were followed for up to 3 years with annual assessments. Muscle and pulmonary function outcomes were analyzed herein. Age-stratified statistical analysis and modeling were conducted to analyze cross-sectional data, time-to-event data, and longitudinal data to characterize these clinical outcomes. Deletion mutations of dystrophin exons 45-47 or 45-48 were most common. Subgroup analysis showed greater pairwise association between motor outcomes at baseline than association between these outcomes and age. Stronger correlations between outcomes for adults than for those under 18 years were also observed. Using cross-sectional binning analysis, a ceiling effect was seen for North Star Ambulatory Assessment but not for other functional outcomes. Longitudinal analysis showed a decline in percentage predicted forced vital capacity over the life span. There was relative stability or improved median function for motor functional outcomes through childhood and adolescence and decreasing function with age thereafter. There is variable progression of outcomes resulting in significant heterogeneity of the clinical phenotype of Becker muscular dystrophy. Disease progression is largely manifest in adulthood. There are implications for clinical trial design revealed by this longitudinal analysis of a Becker natural history dataset.

Sections du résumé

BACKGROUND BACKGROUND
Becker muscular dystrophy is an X-linked, genetic disorder causing progressive degeneration of skeletal and cardiac muscle, with a widely variable phenotype.
OBJECTIVE OBJECTIVE
A 3-year, longitudinal, prospective dataset contributed by patients with confirmed Becker muscular dystrophy was analyzed to characterize the natural history of this disorder. A better understanding of the natural history is crucial to rigorous therapeutic trials.
METHODS METHODS
A cohort of 83 patients with Becker muscular dystrophy (5-75 years at baseline) were followed for up to 3 years with annual assessments. Muscle and pulmonary function outcomes were analyzed herein. Age-stratified statistical analysis and modeling were conducted to analyze cross-sectional data, time-to-event data, and longitudinal data to characterize these clinical outcomes.
RESULTS RESULTS
Deletion mutations of dystrophin exons 45-47 or 45-48 were most common. Subgroup analysis showed greater pairwise association between motor outcomes at baseline than association between these outcomes and age. Stronger correlations between outcomes for adults than for those under 18 years were also observed. Using cross-sectional binning analysis, a ceiling effect was seen for North Star Ambulatory Assessment but not for other functional outcomes. Longitudinal analysis showed a decline in percentage predicted forced vital capacity over the life span. There was relative stability or improved median function for motor functional outcomes through childhood and adolescence and decreasing function with age thereafter.
CONCLUSIONS CONCLUSIONS
There is variable progression of outcomes resulting in significant heterogeneity of the clinical phenotype of Becker muscular dystrophy. Disease progression is largely manifest in adulthood. There are implications for clinical trial design revealed by this longitudinal analysis of a Becker natural history dataset.

Identifiants

pubmed: 37980682
pii: JND230178
doi: 10.3233/JND-230178
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Paula R Clemens (PR)

University of Pittsburgh, Pittsburgh, USA.

Heather Gordish-Dressman (H)

Children's National Medical Center, Washington DC, USA.

Gabriela Niizawa (G)

University of Pittsburgh, Pittsburgh, USA.

Ksenija Gorni (K)

Hoffman-La Roche Inc., Basel, Switzerland.

Michela Guglieri (M)

Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Anne M Connolly (AM)

Nationwide Children's Hospital, Columbus, USA.

Matthew Wicklund (M)

University of Texas Health Science Center at San Antonio, San Antonio, USA.

Tulio Bertorini (T)

University of Tennessee, Memphis, USA.

Jean Mah (J)

Cumming School of Medicine, University of Calgary, Calgary, Canada.

Mathula Thangarajh (M)

Virginia Commonwealth University, Richmond, USA.

Edward C Smith (EC)

Duke University, Durham, USA.

Nancy L Kuntz (NL)

Lurie Children's Hospital, Chicago, USA.

Craig M McDonald (CM)

University of California, Davis, Sacramento, USA.

Erik Henricson (E)

University of California, Davis, Sacramento, USA.

S Upadhyayula (S)

Emory University, Atlanta, USA.

Barry Byrne (B)

University of Florida, Gainesville, USA.

Georgios Manousakis (G)

University of Minnesota, Minneapolis, USA.

Amy Harper (A)

Virginia Commonwealth University, Richmond, USA.

Susan Iannaccone (S)

University of Texas Southwestern Medical Center, Dallas, USA.

Utkarsh J Dang (UJ)

Carleton University, Ottawa, Canada.

Classifications MeSH